SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is currently seeing significant community activity as investors weigh recent reports of a bank acquisition and ongoing speculation regarding potential institutional partnerships. While some traders are expressing frustration over price volatility and volume, others are actively accumulating based on the project's high-speed blockchain claims and its potential role in future financial infrastructure.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders discuss its transition from a niche digital asset into a 'phygital' powerhouse, highlighted by widespread retail presence in major stores and the recent launch of a Visa-backed spending card. The community is actively debating the project's long-term utility and potential for price momentum, with many investors using current market fluctuations as a buying opportunity to DCA into their positions.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

IMSR is trending as investors react to the companys dual Other Transaction Agreements with the U.S. Department of Energy, which aim to accelerate the commercialization of its integral molten salt reactor technology. Community discussions are heavily focused on the stock's potential for a significant valuation rerating as it gains federal support, with bulls drawing comparisons to the market trajectory of established sector peers while debating the company's timeline for achieving reactor criticality.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is under pressure following fourth-quarter earnings that, despite beating consensus estimates, failed to satisfy investor expectations amidst ongoing market volatility. The community is actively discussing the broader banking sector's sensitivity to potential regulatory credit card interest rate caps and shifting economic conditions as traders navigate the fallout from mixed earnings reports across the financial space.

Peabody Energy Corp. engages in the business of coal mining. It operates through the following business segments: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal, and Corporate and Other. The Seaborne Thermal segment consist of mines in New South Wales, Australia. The Seaborne Metallurgical segment includes mines in Queensland, Australia, one in New South Wales, Australia and one in Alabama, USA. The Powder River Basin segment focuses on mines in Wyoming. The Other U.S. Thermal segment reflects on the mining, preparation and sale of thermal coal, sold primarily to electric utilities in the U.S. under long-term contracts, with a relatively small portion sold as international exports as conditions warrant. The Corporate and Other segment involves administrative expenses, results from equity method investments, trading and brokerage activities, minimum charges on certain transportation-related contracts, the closure of inactive mining sites, the impact of foreign currency remeasurement and certain commercial matters. The company was founded by Francis S. Peabody in 1883 and is headquartered in St. Louis, MO.

Peabody Energy Corp. - Ordinary Shares New

Peabody Energy is trending as investors weigh the company's recent operational updates against a broader market push for coal-based energy solutions. The community is actively debating the stock's future, balancing concerns over recent production forecasts and mine-specific challenges with optimism about potential rare earth mineral testing and the sector's long-term role in powering AI data centers.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently capturing significant attention due to its expanding foundry partnerships and progress in integrating proprietary optical polymer technology into silicon photonics platforms, fueling community optimism around its role in the AI data infrastructure race. While some traders are focused on the stock's recent technical breakout and potential for a short squeeze, others remain cautious, debating whether current valuations are justified given the company's long-term commercial timeline and the ongoing volatility across the sector.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention as the company navigates a complex turnaround, with the community closely tracking potential Schedule III rescheduling catalysts and the impact of the new Medicare CBD pilot program. While some shareholders express frustration over past management decisions and performance, many are actively monitoring the stock for a trend reversal, heavily debating the timing of regulatory milestones versus ongoing sector volatility.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing significant volatility as investors weigh the impact of a board-level shakeup against the company's strong underlying growth and earnings performance. The community remains deeply divided, with many retail traders frustrated by price fluctuations while long-term bulls and institutional interest focus on rapid expansion, share buybacks, and an ambitious path toward becoming a broader financial services ecosystem.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as the successful Artemis II mission fuels massive investor enthusiasm for the space infrastructure sector, with the community closely tracking the stock's momentum following significant contract-related developments. Traders are actively debating whether this represents a sustainable long-term breakout or a temporary rally, while excitement builds around the company's expanding role in lunar exploration and upcoming mission milestones.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is facing significant volatility and investor scrutiny as the market weighs concerns over dilutive capital raises and ongoing legal challenges against its long-term potential in the small modular reactor sector. While some market participants are betting on a recovery driven by energy demands from AI data centers, others are closely tracking management's execution and the impact of continued institutional selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galecto (NASDAQ:GLTO) CEO Hans Schambye Sells 700 Shares

Galecto, Inc. (NASDAQ:GLTO - Get Free Report) CEO Hans Schambye sold 700 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $21.38...

Is the Market Bullish or Bearish on Galecto Inc?

Galecto (NASDAQ:GLTO) Shares Down 13.3% - Time to Sell?

Galecto (NASDAQ:GLTO) Stock Price Down 13.3% - Here's Why...

Small Cap Stocks To Watch Today - November 11th

Spring Valley Acquisition, enGene, Canadian Solar, Galecto, RealReal, Daily Journal Corp. (S.C.), and Navitas Semiconductor are the seven Small Cap stocks to watch today, according to MarketBeat's...

Small Cap Stocks To Research - November 10th

Spring Valley Acquisition, Galecto, Movano, Papa John's International, Strive, Inflection Point Acquisition Corp. II, and Direxion Daily PLTR Bull 2X Shares are the seven Small Cap stocks to watch...

<ul class="summary-bullets"><li>Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.</li><li>The deal adds Damora’s portfolio of mutant calreticulin–targeting antibody therapies for rare blood cancers, with early human trial data expected in 2027.</li><li>The acquisition positions Galecto to focus on next-generation treatments for myeloproliferative neoplasms, expanding its cancer pipeline alongside its ongoing AML drug program.</li></ul>Shares of Galecto surged nearly&nbsp;25% in premarket trading on Tuesday after the biotech firm announced the acquisition of Damora Therapeutics, a private company developing next-generation antibody drugs for rare blood cancers.<h2 class="st-heading-2">Galecto Bets Big On Blood Cancer Therapies</h2>The acquisition gives Galecto control of Damora’s pipeline of mutant calreticulin (mutCALR)-targeting therapies, including DMR-001, a monoclonal antibody that aims to treat two difficult-to-manage bone marrow cancers, which are essential thrombocythemia and myelofibrosis. The company said the drug could be “best in class,” with the potential to work across a broad range of disease-driving mutations.As part of the deal, Galecto raised $285 million in a private round that drew some of the biggest names in biotech investing, including Viking Global Investors, RA Capital Management, Wellington Management, Blackstone, BB Biotech, and Andreessen Horowitz’s a16z Bio + Health. The funding gives the company enough cash to operate well into 2029, with early human trial data for DMR-001 expected in 2027.<h2 class="st-heading-2">A New Chapter For Galecto</h2>Galecto CEO Hans Schambye called the deal a “pivotal milestone” that positions the company to accelerate next-generation treatments for blood cancers driven by mutCALR, which account for roughly 25% of essential thrombocythemia and 35% of myelofibrosis cases in the U.S.Incoming board member Peter Harwin, managing partner at Fairmount, said the combined financial and clinical resources will enable Galecto to advance DMR-001 from preclinical to human testing by mid-2026, with the goal of offering a safer, more convenient treatment option for patients.<h2 class="st-heading-2">Growing Its Cancer Pipeline</h2>Beyond Damora’s assets, Galecto said it’s also advancing its own drug, GB3226, for acute myeloid leukemia (AML). The compound will be featured at the American Society of Hematology’s annual meeting in December, with an FDA filing expected in early 2026 to begin human testing.<h2 class="st-heading-2">Stocktwits Users Eye Multi-Day Rally</h2>On Stocktwits, retail sentiment for Galecto was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:962/134;" src="https://news.stocktwits-cdn.com/glto_ss_jpg_87be36e195.webp" alt="glto ss.jpg" width="962" height="134"><figcaption>GLTO sentiment and message volume as of November 11 | Source: Stocktwits</figcaption></figure>One user speculated that Galecto’s stock could turn into a “multi-day runner,” hinting at continued momentum after its sharp surge.<stembedurl>https://stocktwits.com/Bcscoatings/message/635686140</stembedurl>Another user was far more bullish, predicting the stock could hit $50 next and even climb toward $150.<stembedurl>https://stocktwits.com/BearBullRunner/message/635681400</stembedurl><a href="https://stocktwits.com/symbol/GLTO">Galecto’s stock</a> has surged by more than 270% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Galecto Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally

Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.

Equity

Shares of biotechnology company Galecto, Inc. (GLTO) soared 632% in the pre-market session on Tuesday. The stock is on track to hit over two-year highs.Galecto is focused on developing treatments for oncological and liver diseases. Its pipeline consists of drug candidates that target cancer and fibrosis signaling pathways, including GB1211 for the treatment of liver cirrhosis, GB1211 in combination with a checkpoint inhibitor for various oncology indications, and GB3226 for multiple genetic subsets of Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GLTO">GLTO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1362/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_8_17_12_AM_png_631ad32651.webp" alt="GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1362" height="124"><figcaption>GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that this is a pump-and-dump move.<stembedurl>https://stocktwits.com/moneytra1n/message/631281671</stembedurl>Another believes that the rally could be short-lived.<stembedurl>https://stocktwits.com/come_litaliano/message/631283183</stembedurl>In August, Galecto CEO Hans Schambye announced that the company is looking forward to submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first quarter of 2026 for its lead program, GB3226. Preclinical data support the therapeutic potential of the candidate as a monotherapy and in combination to address the menin-resistant population within AML, the company said.Galecto ended the second quarter with approximately $10.2 million in cash and cash equivalents. Last month, it said that it expects this amount to be sufficient to fund operating expenses and capital requirements into 2026, including the submission of the investigational new drug application for GB3226.The company also noted that it would require substantial additional capital to finance its operations, including future clinical development of its GB3226 and GB1211 programs.GLTO stock is down by 20% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jlr-begins-phased-restart-of-operations-more-than-a-month-after-cyber-incident/ch6P7elR3WM">JLR Begins Phased Restart Of Operations More Than A Month After Cyber Incident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious

Galecto is focused on developing treatments for oncological and liver diseases.

Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Current Price	$25.82
Prev Close	$26.69
Open	$27.09
Dividend Yield	0.00%
50-Day Moving Average	$26.26
Beta	2.17
Avg. Volume	287,992.84
PE Ratio	-5.65

52-Week High	$38.33
52-Week Low	$2.33
Market Capitalization	$1.61B
EPS (Annual)	-$3.98
Price to Book	-0.23
Revenue Per Employee	$0.00

GLTO
Galecto Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLTO News

GLTOGalecto Inc